Patents by Inventor George Coricor

George Coricor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb AND USES THEREOF
    Publication number: 20220363741
    Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF? and/or LTBP3-TGF?. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF? activation, and treating subjects suffering from TGF?-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF? inhibitor for a subject in need thereof are also provided.
    Type: Application
    Filed: May 17, 2022
    Publication date: November 17, 2022
    Inventors: Thomas Schurpf, Justin W. Jackson, George Coricor, Abhishek Datta, Stefan Wawersik, Christopher Littlefield, Adam Fogel, Caitlin Stein, Julia McCreary, Matthew Salotto, Frederick Streich, JR.
  • LTBP complex-specific inhibitors of TGF? and uses thereof
    Patent number: 11365245
    Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF? and/or LTBP3-TGF?. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF? activation, and treating subjects suffering from TGF?-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF? inhibitor for a subject in need thereof are also provided.
    Type: Grant
    Filed: November 19, 2021
    Date of Patent: June 21, 2022
    Assignee: Scholar Rock, Inc.
    Inventors: Thomas Schurpf, Justin W. Jackson, George Coricor, Abhishek Datta, Stefan Wawersik, Christopher Littlefield, Adam Fogel, Caitlin Stein, Julia McCreary, Matthew Salotto, Frederick Streich, Jr.
  • LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb AND USES THEREOF
    Publication number: 20220064276
    Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF? and/or LTBP3-TGF?. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF? activation, and treating subjects suffering from TGF?-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF? inhibitor for a subject in need thereof are also provided.
    Type: Application
    Filed: November 19, 2021
    Publication date: March 3, 2022
    Inventors: Thomas SCHURPF, Justin W. JACKSON, George CORICOR, Abhishek DATTA, Stefan WAWERSIK, Christopher LITTLEFIELD, Adam FOGEL, Caitlin STEIN, Julia McCREARY, Matthew SALOTTO, Frederick STREICH, JR.
  • LTBP complex-specific inhibitors of TGF? and uses thereof
    Patent number: 11214614
    Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF? and/or LTBP3-TGF?. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF? activation, and treating subjects suffering from TGF?-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF? inhibitor for a subject in need thereof are also provided.
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: January 4, 2022
    Assignee: Scholar Rock, Inc.
    Inventors: Thomas Schurpf, Justin W. Jackson, George Coricor, Abhishek Datta, Stefan Wawersik, Christopher Littlefield, Adam Fogel, Caitlin Stein, Julia McCreary, Matthew Salotto, Frederick Streich, Jr.
  • LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb AND USES THEREOF
    Publication number: 20210047396
    Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF? and/or LTBP3-TGF?. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF? activation, and treating subjects suffering from TGF?-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF? inhibitor for a subject in need thereof are also provided.
    Type: Application
    Filed: August 19, 2020
    Publication date: February 18, 2021
    Inventors: Thomas Schurpf, Justin W. Jackson, George Coricor, Abhishek Datta, Stefan Wawersik, Christopher Littlefield, Adam Fogel, Caitlin Stein, Julia McCreary, Matthew Salotto, Frederick Streich